Introduction: Therapeutic options for metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC) which is often considered to show a biological behavior similar to NEC.
Aim(s): To analyze the efficacy of topotecan in pretreated metastatic NEC patients.
Materials and methods: We performed an updated retrospective analysis of all patients treated with topotecan for metastatic NEC who presented at our center between January 2005 and December 2013.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. med. Leonidas Apostolidis
To read results and conclusion, please login ...
Further abstracts you may be interested in